

January 7, 2015



## DelMar Pharmaceuticals to Present at Biotech Showcase™ 2015

VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 7, 2015 /PRNewswire/ - [DelMar Pharmaceuticals, Inc.](#) (OTCQX: DMPI) ("DelMar", the "Company") announced today that Jeffrey Bacha, DelMar's president & CEO, will be presenting at the Biotech Showcase™ 2015 Conference being held in San Francisco, CA.

Mr. Bacha will outline DelMar's goals for the coming year and provide an update on the Company's ongoing clinical trial with VAL-083, which is being developed as a potential new chemotherapy for the treatment of refractory glioblastoma multiforme (GBM).

Details of DelMar's presentation are as follows:

**Event:** Biotech Showcase™ 2015 Conference  
**Date:** Wednesday January 14, 2015  
**Time:** 1:45PM PST / 4:45PM EST  
Mission Room #2: Parc 55 Wyndham San Francisco Union Square  
**Location:** Hotel

A live webcast link to view Mr. Bacha's Biotech Showcase™ presentation will be available at <http://edge.media-server.com/m/p/2edjycvj> and available for playback for 30 days on DelMar's website for those unable to attend in person.

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with investors and pharmaceutical executives during one of the industry's largest annual healthcare investor conferences. Biotech Showcase is co-produced by Demy-Colton Life Science Advisors and EBD Group. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

### **About DelMar Pharmaceuticals, Inc.**

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

### **About Demy-Colton Life Science Advisors**

Demy-Colton Life Science Advisors is focused exclusively on facilitating the growth of the life science industry. Now going into its fifth year, Demy-Colton has developed a number of high-value added conferences to address the business and development needs of the biotechnology industry; it provides partnering services and it has helped launch a unique investor website and newsletter. For more information please visit [www.demy-colton.com](http://www.demy-colton.com).

### **About EBD Group**

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. For more information please visit [www.ebdgroup.com](http://www.ebdgroup.com) or follow EBD Group on Twitter at [twitter.com/ebdgroup](https://twitter.com/ebdgroup).

For more information, please visit [www.delmarpharma.com](http://www.delmarpharma.com) or follow us on Twitter [@delmarpharma](https://twitter.com/delmarpharma) or [Facebook.com/delmarpharma](https://www.facebook.com/delmarpharma).

### **Safe Harbor Statement**

*Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.*

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-present-at-biotech-showcase-2015-300017027.html>

SOURCE DelMar Pharmaceuticals, Inc.